A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): Responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67

Bojana Jovanovic, Ingrid A. Mayer, Erica L. Mayer, Vandana G. Abramson, Aditya Bardia, Melinda E. Sanders, M. Gabriela Kuba, Monica V. Estrada, J. Scott Beeler, Timothy M. Shaver, Kimberly C. Johnson, Violeta Sanchez, Jennifer M. Rosenbluth, Patrick M. Dillon, Andres Forero-Torres, Jenny C. Chang, Ingrid M. Meszoely, Ana M. Grau, Brian D. Lehmann, Yu ShyrQuanhu Sheng, Sheau Chiann Chen, Carlos L. Arteaga, Jennifer A. Pietenpol

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: Because of inherent disease heterogeneity, targeted therapies have eluded triple-negative breast cancer (TNBC), and biomarkers predictive of treatment response have not yet been identified. This study was designed to determine whether the mTOR inhibitor everolimus with cisplatin and paclitaxel would provide synergistic antitumor effects in TNBC. Methods: Patients with stage II/III TNBC were enrolled in a randomized phase II trial of preoperative weekly cisplatin, paclitaxel and daily everolimus or placebo for 12 weeks, until definitive surgery. Tumor specimens were obtained at baseline, cycle 1, and surgery. Primary endpoint was pathologic complete response (pCR); secondary endpoints included clinical responses, breast conservation rate, safety, and discovery of molecular features associated with outcome. Results: Between 2009 and 2013, 145 patients were accrued; 36% of patients in the everolimus arm and 49% of patients in the placebo arm achieved pCR; in each arm, 50% of patients achieved complete responses by imaging. Higher rates of neutropenia, mucositis, and transaminase elevation were seen with everolimus. Clinical response to therapy and long-term outcome correlated with increased frequency of DNA damage response (DDR) gene mutations, Basal-like1 and Mesenchymal TNBC-subtypes, AR-negative status, and high Ki67, but not with tumor-infiltrating lymphocytes. Conclusions: The paclitaxel/cisplatin combination was well tolerated and active, but addition of everolimus was associated with more adverse events without improvement in pCR or clinical response. However, discoveries made from correlative studies could lead to predictive TNBC biomarkers that may impact clinical decision-making and provide new avenues for mechanistic exploration that could lead to clinical utility.

Original languageEnglish
Pages (from-to)4035-4045
Number of pages11
JournalClinical Cancer Research
Volume23
Issue number15
DOIs
Publication statusPublished - 2017 Aug 1

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): Responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67'. Together they form a unique fingerprint.

  • Cite this

    Jovanovic, B., Mayer, I. A., Mayer, E. L., Abramson, V. G., Bardia, A., Sanders, M. E., Kuba, M. G., Estrada, M. V., Beeler, J. S., Shaver, T. M., Johnson, K. C., Sanchez, V., Rosenbluth, J. M., Dillon, P. M., Forero-Torres, A., Chang, J. C., Meszoely, I. M., Grau, A. M., Lehmann, B. D., ... Pietenpol, J. A. (2017). A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): Responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67. Clinical Cancer Research, 23(15), 4035-4045. https://doi.org/10.1158/1078-0432.CCR-16-3055